Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
Missing Details Should Prompt Suspicion
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
You may also be interested in...
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?
Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data
Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.